A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment

As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naïve high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherap...

Full description

Bibliographic Details
Main Authors: Ja Min Byun, Ho Young Kim, Seung-Hyun Nam, Ho-Jin Shin, Seulki Song, Jinny Park, Sang Hoon Han, Yong Park, Young Jin Yuh, Yeung-Chul Mun, Young Rok Do, Sang Kyun Sohn, Sung Hwa Bae, Dong-Yeop Shin, Sung-Soo Yoon
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
essential thrombocythemia
high risk
Anagrelide
phase IV clinical trial
myeloproliferative neoplasms
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.989984/full

Similar Items

Similar Items